ARTICLE SUMMARY:
Medtronic’s renal denervation business is preparing for US-wide expansion now that the therapy is FDA approved to treat uncontrolled hypertension and reimbursed by Medicare nationwide.
CMS’ recent decision to mandate national Medicare coverage for renal denervation (RDN) within a CMS-approved study marks a major milestone for the physicians and companies who have long believed in the therapy’s potential to help patients with uncontrolled hypertension.
